Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Covington
Chinese Patent Office
Cantor Fitzgerald
Novartis
Medtronic
US Department of Justice
Cipla
Johnson and Johnson
Queensland Health
Colorcon

Generated: October 19, 2017

DrugPatentWatch Database Preview

Lifitegrast - Generic Drug Details

« Back to Dashboard

What are the generic sources for lifitegrast and what is the scope of lifitegrast freedom to operate?

Lifitegrast
is the generic ingredient in one branded drug marketed by Shire Dev Llc and is included in one NDA. There are thirteen patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Lifitegrast has ninety-three patent family members in twenty countries.

One supplier is listed for this compound.

Summary for Generic Name: lifitegrast

US Patents:13
Tradenames:1
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list1
Clinical Trials: see list6
Patent Applications: see list48
Drug Prices:see low prices
DailyMed Link:lifitegrast at DailyMed

Pharmacology for Ingredient: lifitegrast

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Shire Dev Llc
XIIDRA
lifitegrast
SOLUTION/DROPS;OPHTHALMIC208073-001Jul 11, 2016RXYesYes► Subscribe► Subscribe ► Subscribe
Shire Dev Llc
XIIDRA
lifitegrast
SOLUTION/DROPS;OPHTHALMIC208073-001Jul 11, 2016RXYesYes► Subscribe► SubscribeY ► Subscribe
Shire Dev Llc
XIIDRA
lifitegrast
SOLUTION/DROPS;OPHTHALMIC208073-001Jul 11, 2016RXYesYes► Subscribe► Subscribe ► Subscribe
Shire Dev Llc
XIIDRA
lifitegrast
SOLUTION/DROPS;OPHTHALMIC208073-001Jul 11, 2016RXYesYes► Subscribe► SubscribeYY ► Subscribe
Shire Dev Llc
XIIDRA
lifitegrast
SOLUTION/DROPS;OPHTHALMIC208073-001Jul 11, 2016RXYesYes► Subscribe► Subscribe► Subscribe
Shire Dev Llc
XIIDRA
lifitegrast
SOLUTION/DROPS;OPHTHALMIC208073-001Jul 11, 2016RXYesYes► Subscribe► Subscribe ► Subscribe
Shire Dev Llc
XIIDRA
lifitegrast
SOLUTION/DROPS;OPHTHALMIC208073-001Jul 11, 2016RXYesYes► Subscribe► SubscribeYY ► Subscribe
Shire Dev Llc
XIIDRA
lifitegrast
SOLUTION/DROPS;OPHTHALMIC208073-001Jul 11, 2016RXYesYes► Subscribe► SubscribeY ► Subscribe
Shire Dev Llc
XIIDRA
lifitegrast
SOLUTION/DROPS;OPHTHALMIC208073-001Jul 11, 2016RXYesYes► Subscribe► SubscribeY ► Subscribe
Shire Dev Llc
XIIDRA
lifitegrast
SOLUTION/DROPS;OPHTHALMIC208073-001Jul 11, 2016RXYesYes► Subscribe► SubscribeYY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: lifitegrast

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,248,126Modulators of cellular adhesion► Subscribe
9,051,297Compositions and methods for treatment► Subscribe
8,080,562Crystalline pharmaceutical and methods of preparation and use thereof► Subscribe
8,758,776Compositions and methods for treatment► Subscribe
7,989,626Modulators of cellular adhesion► Subscribe
9,708,303LFA-1 inhibitor and methods of preparation and polymorph thereof► Subscribe
9,045,458Compositions and methods for treatment► Subscribe
8,378,105Crystalline pharmaceutical and methods of preparation and use thereof► Subscribe
8,071,617Modulators of cellular adhesion► Subscribe
8,871,935Crystalline pharmaceutical and methods of preparation and use thereof► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: lifitegrast

Country Document Number Estimated Expiration
Japan5840582► Subscribe
Mexico2010004281► Subscribe
South Korea20150067129► Subscribe
Japan2016147908► Subscribe
World Intellectual Property Organization (WIPO)2009128933► Subscribe
Hong Kong1210782► Subscribe
Japan2011521896► Subscribe
Cyprus1112844► Subscribe
World Intellectual Property Organization (WIPO)2014018748► Subscribe
European Patent Office1881823► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Deloitte
Citi
Dow
Colorcon
Medtronic
McKinsey
Farmers Insurance
Baxter
UBS
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot